Graft Polymer (GPL) has announced it has been contracted to produce a patented haemostatic powder following a recent successful pilot scheme and with its production facility in Slovenia now fully operational. What of the shares currently approaching 3p, up over 30%, in response?
In today's bearcast I look at Kefi Gold & Copper (KEFI) on what is a great day for we loyal shareholders, Wildcat Petroleum (WCAT), Graft Polymer (GPL) - should that be Grift Polymer - and MGC Pharmaceuticals (MXC). Then it is onto Versarien (VRS) and the Neill Ricketts payoff and bailout placing and Pensana (PRE) which must by now be at death's door: a £55 million market cap looks full in the circumstances and a statement is needed. Finally, that old scallywag Lenigas of Pennpetro (PPP) has doubled down after my earlier expose. He would not dare behave like this in America.
Graft Polymer (GPL) states that it “is pleased to announce its audited results for the 12 months to 31 December 2022” and that it “continue to establish the stepping stones for growth and look forward to reporting our progress to shareholders during 2023”. So what of the shares currently responding to 5.5p, more than 30% lower?!